INTRODUCTION {#sec1-1}
============

Injuries arising from brain trauma are among the causes of death and severe disabilities. Management of brain traumatic injuries includes prevention of neurological complications, intracranial pressure monitoring, and surgical procedures. Finding drugs which are effectively neuroprotective is of special importance for prevention of secondary brain injury after trauma. Attempts have been made, for more than 30 years, to discover an effective and harmless compound which acts as a neuroprotective in brain injuries.\[[@ref1]\] During last two decades, all the clinical trials phase II and III for the moderate and severe traumatic brain injuries failed.\[[@ref1]\] So far, 130 drugs have been effective on brain injury in animal samples,\[[@ref2]\] although they were not effective in clinical trials and do not have any neuroprotective effects.\[[@ref2][@ref3]\] One reason is the complexity and diversity of the mechanisms related to different types of TBI, which are not cured by a single drug and cover only one or few receptors.\[[@ref1][@ref4]\] Among the studied drugs, progesterone (PROG) has been identified as an effective and safe compound, which is a neuroactive steroidal hormone having neurosteroidal activity in central nervous system.\[[@ref5]--[@ref7]\] In traumatic brain injuries and strokes, this hormone causes blood-brain barrier protection, cerebral edema reduction, inflammatory response, necrosis and apoptosis and stimulation of myelin formation, free radicals reduction, and neuronal loss reduction.\[[@ref8]--[@ref11]\]

Similar to progesterone, vitamin D (VDH) is a neurosteroid acting like a PROG in neuroprotective process.\[[@ref1]\] It causes the expression of more than 1000 genes that consequently results in activation of many pathways in CNS (central nervous system).\[[@ref12]\] Therefore, VHD in combination with PROG may cure the patients. Recent studies have shown that vitamin D deficiency may intensify traumatic brain injury and reduce the effects of other therapies for TBI. This problem becomes important with respect to the elderly, since, of whom more than 50% suffer from vitamin D deficiency.\[[@ref13]\] There are evidences that 30 to 50% of American people suffer from vitamin D deficiency, so that, all the patients with TBI of any age are at risk of unfavorable outcome.\[[@ref13]\] Given that the studies examining the effect of the combined PROG and VDH on neural recovery after TBI were most conducted on animals, the present study assessed the effect of these two compounds on outcome improvement in patients with TBI.

MATERIALS AND METHODS {#sec1-2}
=====================

This clinical trial was performed in Alzahra Hospital, Isfahan, Iran, in 2010.

Inclusion criteria of the study {#sec2-1}
-------------------------------

Patients with brain trauma and diffuse axonal injuryPatients with GCS \< 8

Exclusion criteria of the study {#sec2-2}
-------------------------------

Patient\'s legal representative does not consent to patient\'s participation in the study.

Sampling method {#sec2-3}
---------------

Simple random

Number of samples {#sec2-4}
-----------------

20 patients were selected in each group through simple random sampling.

The patients were randomly divided into 3 groups, each with 20 people. Within 8 hours after traumatic injury, the patients in the first group were injected 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days, and the patients in the second group were injected 1 mg/kg of progesterone intramuscularly every 12 hours for 5 days and also 5 μg/kg vitamin D once-a-day for 5 days. The third group as the control group received placebo (Both placebos were injected intravenously). Patients' level of consciousness was periodically controlled based on Glasgow Coma Scale (GCS) during hospitalization and 1 month after treatment, and Glasgow Outcome Scale (GOS) was controlled after 3 months. GOS criteria were defined as follows:

5 = Good recovery: Normal or near normal recovery

4 = Moderate disability: Disable but independent

3 = Severe disability: Dependent with physical / psychological disabilities

2 = Persistent vegetative state

1 = Dead

Finally, these criteria were divided into 2 categories of "favorable" (good recovery and moderate disability) and "unfavorable" (the other 3 criteria).\[[@ref5]\] Analysis of the data was done using SPSS 18 software. Qualitative and quantitative data of the groups were compared using Chi square and One-way ANOVA tests, respectively. Comparison of GCS and GOS variations, before and after intervention and among the 3 groups, was done using repeated measurement ANOVA.

RESULTS {#sec1-3}
=======

This study was carried out in Trauma Center of Alzahra Hospital, Isfahan, Iran, from April to September, 2011. 3 groups of 20 patients were studied and followed up over 3 months.\[[@ref5]\] Demographic specifications showed no significant difference among the 3 groups, i.e., the patients were matched in this regard \[[Table 1](#T1){ref-type="table"}\].

###### 

Clinical and demographic characteristics between 3 groups

![](ABR-1-58-g001)

Before intervention, GCS mean of the placebo, progesterone, and progesterone-vitamin D groups comprised 6.3 ± 0.88, 6.31 ± 0.87, and 6 ± 0.88, respectively, which 3 months after intervention, increased to 9.16 ± 1.11, 10.25 ± 1.34, and 11.27 ± 2.27, respectively. There was a significant difference among GCS means of the 3 groups (*P*-value = 0.001) \[[Figure 1](#F1){ref-type="fig"}\].

![Comparison of GCS at administration and 3 month later between 3 groups](ABR-1-58-g002){#F1}

GOS values of the patients, 3 months after trauma, are shown in [Table 2](#T2){ref-type="table"}. Recovery rate in the group receiving progesterone and vitamin D together was higher than that of other groups; consequently, mortality rate in this group was less than that of others (*P*-value = 0.03).

###### 

Comparison of Glasgow outcome Scale scores between the progesterone, progesterone--Vitamin D, and placebo groups at 3 months later

![](ABR-1-58-g003)

Favorable responses in placebo, progesterone, and progesterone-vitamin D comprised 25%, 45%, and 60%, respectively which showed a statistical significant difference among the groups (*P*-value = 0.03) \[[Figure 2](#F2){ref-type="fig"}\].

![Comparison of dichotomized Glasgow Outcome scale score for patients receiving placebo or progesterone or progesterone and vitamin D after 3 month](ABR-1-58-g004){#F2}

In this study, mean mortality rate was 23.3% (14 patients) as the mortality rate in the placebo, progesterone-vitamin D, and progesterone groups was 40% (8 patients), 10% (2 patients), and 20% (4 patients), respectively. These rates showed a significant difference among groups (*P*-value = 0.000).

DISCUSSION {#sec1-4}
==========

Numerous studies have been done on TBI treatment. However, most of them were conducted under *in vitro* and *in vivo* conditions. There have been also few studies on TBI treatment with combined progesterone and vitamin D, especially on human samples. In this study, progesterone and progesterone-vitamin D were found to improve the patients' outcome as the recovery rate in the group with combination therapy was significantly more than that in other groups. Moreover, GCS variations and mortality rate in the group with combination therapy were significantly less than those in other groups. Favorable outcome of the group with combination therapy was significantly more than those in other groups. A similar study performed under *in vitro* condition\[[@ref1]\] showed that low dose PROG (0.01, 0.1, and 1.5 μmol/l) did not reduce glutamate-induced cell death, whereas with higher doses (10, 24, 40, and 80 μmol/l), PROG significantly reduced LDH and MTT as the optimum dose of PROG was reported as 20 μmol/l. Furthermore, therapeutic responses to vitamin D were found to have a U-shaped pattern as the most favorable response was found in low doses (0.001 - 0.5 μmol/l), and the least neuroprotective effect was found in higher doses (1 - 10 μmol/l).\[[@ref1]\] In the above study, the combination of vitamin D (0.1 μmol/l) and PROG (20 μmol/l) showed no significant preventive effect than the other group, and this was contrary to the U-shaped pattern of response to vitamin D; however, the combined PROG (20 μmol/l) and VDH (20 μmol/l) significantly reduced cell death and was more effective than any of the drugs alone.

Another study on the effect of progesterone alone showed more favorable outcome and much less mortality rate for the patients in progesterone group.\[[@ref5]\]

The effect of progesterone on σ1 receptor acts as a competitive inhibitor and may reduce N-methyl-D-aspartate (NMDA) glutamate signaling.\[[@ref14][@ref15]\] Moreover, PROG affects nicotinic acetylcholine receptor (nAChR)\[[@ref16]\] and stimulates gamma-aminobutyric acid (GABA) as the most important inhibition transmitter in brain. All the above 3 mechanisms are responsible for the positive neuroprotective effects of PROG as they inhibit the excitotoxic responses in injuries.\[[@ref13]\]

Vitamin D belongs to the secosteroid class, which directly causes the expression of more than 100 genes.\[[@ref17]\] This neuroactive steroid can be dispersed in CNS since it is the final activator of enzymes and has an intracellular receptor. The primary effects of vitamin D are the inhibition of cell proliferation and stimulation of cellular differentiation, especially in immune system.\[[@ref18][@ref19]\] It has been found that vitamin D deviates all the dimensions of immune performance, which is near the immune response type 2 and generally is anti-inflammatory and regulatory.\[[@ref13]\] Similar to progesterone, vitamin D reduces the pro-inflammatory level of TH1 cytokines such as IL6, IL12, IL1B, and TNFα.\[[@ref20]\] Furthermore, vitamin D maintains the intracellular surface of calcium through following ways: 1. Maintenance of PTH at an appropriate level, 2. Adjustment of L-type voltage-sensitive calcium channels, and 3. Control of intracellular Ca^2+^ buffering.

The progesterone activity through GABAergic system to inhibit extracellular activity and the performance of vitamin D to increase intracellular Ca^2+^-binding proteins together affect the calcium metabolism through sub-pathways.

Other reasons for the use of combined PROG and vitamin D in TBI treatment are as follows:

Reduction of the effects of glutamate release and calcium inflexProtection against toxic effects of heme breakdown productsEnhancement of free radical scavengingModulation of the renin-angiotensin systemProtection of the axonal and cytoskeleton infrastructure

CONCLUSION {#sec1-5}
==========

As mentioned before, vitamin D and progesterone are pleiotropic hormones with a lot of common pathways, which consequently reduce the CNS injury and increase recovery rate of nervous system after TBI. Many studies performed on mice and humans have reported significant favorable outcome after TBI.\[[@ref21]--[@ref23]\] Recently, progesterone has been found to reduce inflammatory response and oxidative stress.\[[@ref24][@ref25]\] Moreover, progesterone activates the protective pathways and increases the expression of genes and proteins related to neuroprotection after TBI.\[[@ref13]\] There are also reports about the neuroprotective effect of vitamin D under *in vitro* and *in vivo* conditions and cortical infarcts.\[[@ref26]\] Furthermore, studies have shown that vitamin D deficiency disrupts the processes associated with CNS health such as mitosis, mitogenesis, neurite outgrowth, possibly adult neurogenesis in hippocampal cells, and mitochondria function.\[[@ref27]\]

Regarding the foregoing, the use of combined PROG and vitamin D is reasonable in that vitamin D in combination with PROG improves repair mechanisms of CNS considering their common pathways, and also compensates other mechanisms, which are not performed by PROG. This reduces the heterogeneity of TBI and the probable failure of a single treatment.
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